Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 17/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30309528 | 1.00 | FGFR4 (0.38) | FGFR4FGFR1LCKMAPK14SMN1; SMN2 | |
| SCHEMBL25882482 | 0.85 | FGFR4 (0.37) | FGFR4FGFR1LCKMAPK14 | |
| SCHEMBL30309508 | 0.81 | FGFR4 (0.40) | FGFR4FGFR1 | |
| SCHEMBL23978369 | 0.81 | FGFR4 (0.40) | FGFR4FGFR1 | |
| SCHEMBL25882416 | 0.79 | SIK2 (0.46) | FGFR4FGFR1LCKMAPK14 | |
| SCHEMBL30309486 | 0.79 | SIK2 (0.46) | FGFR4FGFR1LCKMAPK14 | |
| SCHEMBL25314439 | 0.74 | CSF1R (0.57) | FGFR4 | |
| SCHEMBL25882488 | 0.74 | SMN1; SMN2 (0.32) | SMN1; SMN2 | |
| SCHEMBL16071527 | 0.72 | FGFR4 (0.65) | FGFR4FGFR1 | |
| SCHEMBL16071406 | 0.68 | FGFR4 (0.72) | FGFR4FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192701-A1 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-06-22 | — | — | US | disclosed |
| US-20230192701-A1 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-06-22 | — | — | US | disclosed |
| WO-2021219731-A2 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192701-A1 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | MITF, PRKDC, PRKACA | FGFR4 845/4885FGFR1 137/4885LCK 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.